Drugs / Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes
Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00393029 | Oct 2006 → Nov 2008 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes | “Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes” NCT00393029 ↗ |
| Route | Intravenous | “Patients receive an IV infusion of the transduced cells containing anti-p53 protein” NCT00393029 ↗ |